[DPLO] Diplomat Pharmacy, Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Nursing Services

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 12.99 Change: -0.02 (-0.15%)
Ext. hours: Change: 0 (0%)

chart DPLO

Refresh chart

Strongest Trends Summary For DPLO

DPLO is in the long-term down -82% below S&P in 2 years and down -91% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotech and specialty pharmaceuticals. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company offers its solutions in range of specialty therapeutic categories, including oncology, immunology, hepatitis, multiple sclerosis, HIV, and infusion therapy. Diplomat Pharmacy, Inc. has seven pharmacy locations in Michigan, Illinois, Florida, California, Connecticut, and Massachusetts. The company was founded in 1975 and is headquartered in Flint, Michigan.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 15.36% Sales Growth - Q/Q2.09% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA1.09% ROE1.86% ROI
Current Ratio2.09 Quick Ratio1.58 Long Term Debt/Equity Debt Ratio0.66
Gross Margin6.39% Operating Margin0.48% Net Profit Margin0.25% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities152.07 M Cash From Investing Activities-3.91 M Cash From Operating Activities-4.1 M Gross Profit41.14 M
Net Profit2.86 M Operating Profit4.84 M Total Assets544.8 M Total Current Assets444.79 M
Total Current Liabilities212.69 M Total Debt4.7 M Total Liabilities224.46 M Total Revenue624.88 M
Technical Data
High 52 week21.15 Low 52 week4.31 Last close4.69 Last change2.18%
RSI24 Average true range0.25 Beta1.12 Volume808.56 K
Simple moving average 20 days-6% Simple moving average 50 days-13.56% Simple moving average 200 days-33.15%
Performance Data
Performance Week-1.26% Performance Month-16.55% Performance Quart-12.66% Performance Half-14.57%
Performance Year-77.39% Performance Year-to-date-69.14% Volatility daily2.13% Volatility weekly4.77%
Volatility monthly9.77% Volatility yearly33.85% Relative Volume189.12% Average Volume742.77 K
New High New Low


2019-11-15 06:40:28 | Diplomat Pharmacy, Inc. Just Reported And Analysts Have Been Cutting Their Estimates

2019-11-14 01:55:56 | Edited Transcript of DPLO earnings conference call or presentation 12-Nov-19 1:30pm GMT

2019-11-13 16:25:08 | Diplomat Pharmacy Analysts Weigh Takeout Scenarios, Valuation After Going Concern Warning

2019-11-13 07:10:18 | The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher

2019-11-12 17:03:13 | Diplomat Pharmacy, Inc. -- Moody's downgrades Diplomat Pharmacy to Caa1; developing outlook

2019-11-12 15:36:00 | Diplomat Pharmacy’s stock plunges toward record low after ‘going concern’ warning

2019-11-12 14:11:13 | Diplomat Pharmacy Has 'Substantial Doubt' It Can Continue Operations

2019-11-12 08:55:01 | Diplomat Pharmaceuticals DPLO Reports Q3 Loss, Tops Revenue Estimates

2019-11-12 07:30:00 | Diplomat Announces 3rd Quarter Financial Results; Updates 2019 Guidance

2019-11-06 14:14:51 | Hedge Funds Have Never Been Less Bullish On Diplomat Pharmacy Inc DPLO

2019-10-30 16:30:00 | Diplomat to Release Third-Quarter 2019 Operating Results Nov. 12

2019-10-18 07:49:31 | Imagine Owning Diplomat Pharmacy NYSE:DPLO And Trying To Stomach The 82% Share Price Drop

2019-10-16 16:30:00 | Diplomat Announces Sale of Certain Assets of Envoy Health Management, LLC to Diligent Health Solutions, LLC

2019-10-02 16:30:00 | Diplomat Announces Promotion of David Skomo to Chief Operating Officer of CastiaRx

2019-09-02 12:37:31 | Does Diplomat Pharmacy NYSE:DPLO Have A Healthy Balance Sheet?

2019-08-14 14:36:00 | Diplomat Pharmacy Considers Its Options

2019-08-10 15:45:36 | Edited Transcript of DPLO earnings conference call or presentation 9-Aug-19 12:30pm GMT

2019-08-09 19:23:23 | Diplomat Pharmacy Inc DPLO Q2 2019 Earnings Call Transcript

2019-08-09 15:31:10 | Diplomat Pharmacy, Inc. -- Moody's downgrades Diplomat Pharmacy to B3; outlook developing

2019-08-09 07:56:00 | Diplomat Pharmacy's stock climbs after potential sale considered as it reported a wider loss

2019-08-09 07:53:37 | Diplomat Pharmacy Reports Q2 Earnings Beat, Will Explore Strategic Alternatives

2019-08-09 07:31:00 | Diplomat Announces 2nd Quarter Financial Results; Updates 2019 Guidance

2019-08-09 07:30:00 | Diplomat Announces Review of Strategic Alternatives

2019-08-08 17:30:00 | Diplomat signs exclusive practice-based infusion agreement with Allergy Partners

2019-08-08 14:13:09 | Diplomat Pharmacy's Q2 Earnings Preview

2019-08-02 10:30:02 | Analysts Estimate Diplomat Pharmaceuticals DPLO to Report a Decline in Earnings: What to Look Out for

2019-08-01 09:27:43 | Is Diplomat Pharmacy, Inc. NYSE:DPLO Trading At A 41% Discount?

2019-07-18 16:30:00 | Diplomat to Release Second-Quarter 2019 Operating Results August 9

2019-07-15 11:23:00 | DPLO Alert: Johnson Fistel, LLP Announces Investigation of Diplomat Pharmacy, Inc.; Long Term Investors Encouraged to Contact Firm

2019-07-09 16:30:00 | Diplomat Launches Empower Ecosystem Patient Support Digital Library

2019-06-27 13:21:15 | Rite Aid RAD Incurs Loss in Q1, Revenues Decline Y/Y

2019-06-26 18:29:41 | Here’s What Hedge Funds Think About Diplomat Pharmacy Inc DPLO

2019-06-26 13:26:43 | Is It Too Late To Consider Buying Diplomat Pharmacy, Inc. NYSE:DPLO?

2019-06-26 13:23:22 | Is There Now An Opportunity In Diplomat Pharmacy, Inc. NYSE:DPLO?

2019-06-10 07:00:43 | How Does Investing In Diplomat Pharmacy, Inc. NYSE:DPLO Impact The Volatility Of Your Portfolio?

2019-05-23 13:23:13 | Diplomat Pharmacy, Inc. -- Moody's announces completion of a periodic review of ratings of Diplomat Pharmacy, Inc.

2019-05-13 16:54:00 | Waiting on Diplomat Pharmacy to Rebuild

2019-05-10 10:31:02 | New Strong Sell Stocks for May 10th

2019-05-07 15:27:23 | Edited Transcript of DPLO earnings conference call or presentation 7-May-19 12:30pm GMT

2019-05-07 13:23:28 | Diplomat Pharmacy Inc DPLO Q1 2019 Earnings Call Transcript

2019-05-07 09:05:01 | Diplomat Pharmaceuticals DPLO Reports Q1 Loss, Tops Revenue Estimates

2019-05-07 07:59:18 | Diplomat Pharmaceuticals: 1Q Earnings Snapshot

2019-05-07 07:30:00 | Diplomat Announces 1st Quarter Financial Results

2019-05-06 16:30:00 | Diplomat Appoints Dave Loschinskey as Chief Operating Officer

2019-05-03 10:15:14 | Is Diplomat Pharmacy Inc DPLO A Good Stock To Buy?

2019-04-30 10:32:02 | Diplomat Pharmaceuticals DPLO Expected to Beat Earnings Estimates: Should You Buy?

2019-04-30 07:15:00 | NYSE: DPLO Investor Notice: Lawsuit against Diplomat Pharmacy Inc announced by Shareholders Foundation

2019-04-25 21:27:18 | APRIL 25 DEADLINE: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Diplomat Pharmacy, Inc. DPLO and Encourages DPLO Investors to Contact the Firm

2019-04-25 17:50:00 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DPLO, INGN and BPI

2019-04-25 16:30:00 | Diplomat Using SMRxT Technology to Enhance Patient Care